These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17707544)

  • 1. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
    Lévi F; Focan C; Karaboué A; de la Valette V; Focan-Henrard D; Baron B; Kreutz F; Giacchetti S
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1015-35. PubMed ID: 17692427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling.
    Altinok A; Lévi F; Goldbeter A
    Eur J Pharm Sci; 2009 Jan; 36(1):20-38. PubMed ID: 19041394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronotherapy of cancer: biological basis and clinical application.
    Lévi F
    Pathol Biol (Paris); 1994 Apr; 42(4):338-41. PubMed ID: 7808787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dynamic circadian system patients under chimiotherapy].
    Beau J; Iurisci I; Beau T; Lévi F
    Pathol Biol (Paris); 2007; 55(3-4):171-5. PubMed ID: 17412521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.
    Caussanel JP; Lévi F; Brienza S; Misset JL; Itzhaki M; Adam R; Milano G; Hecquet B; Mathé G
    J Natl Cancer Inst; 1990 Jun; 82(12):1046-50. PubMed ID: 2348469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cell cycle automaton model for probing circadian patterns of anticancer drug delivery.
    Altinok A; Lévi F; Goldbeter A
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1036-53. PubMed ID: 17692993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronobiology and cancer].
    Lévi F
    Pathol Biol (Paris); 1987 Jun; 35(6):960-8. PubMed ID: 3306577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation.
    Clairambault J
    IEEE Eng Med Biol Mag; 2008; 27(1):20-4. PubMed ID: 18270046
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
    Barbolosi D; Freyer G; Ciccolini J; Iliadis A
    Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological perspectives on circadian cancer therapy.
    Wood PA; Hrushesky WJ
    J Infus Chemother; 1995; 5(4):182-90. PubMed ID: 8934723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The circadian-timing system: a determinant of drug activity and a target of anticancer treatments].
    Lévi F
    Ann Pharm Fr; 2008 Jun; 66(3):175-84. PubMed ID: 18706346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seasonal modulation of the 8-and 24-hour rhythms of ondansetron tolerance in mice.
    Khedhaier A; Ben-Attia M; Gadacha W; Sani M; Reinberg A; Boughattas NA
    Chronobiol Int; 2007; 24(6):1199-212. PubMed ID: 18075807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of heated intraperitoneal oxaliplatin.
    Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy may be delivered based on an integrated view of tumour dynamics.
    Ribba B; You B; Tod M; Girard P; Tranchand B; Trillet-Lenoir V; Freyer G
    IET Syst Biol; 2009 May; 3(3):180-90. PubMed ID: 19449978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow osteosarcoma induced in mice: a mathematical model].
    Clairambault J; Claude D; Filipski E; Granda T; Lévi F
    Pathol Biol (Paris); 2003 Jun; 51(4):212-5. PubMed ID: 12852993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination effects of SC144 and cytotoxic anticancer agents.
    Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
    Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of the chronotherapeutic index in the experimental animal laboratory.
    Halberg E; Cornélissen G; Halberg F
    In Vivo; 1992; 6(4):371-85. PubMed ID: 1520840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.